Ibio, Inc. · NASDAQ:IBIO
Ibio — Investor Presentation (January 2025)
81 slides from Ibio's investor presentation, Jan 10, 2025
Slide 1: Breakthrough Antibodies for Obesity and Cardiometabolic Diseases
Breakthrough Antibodies for Obesity and Cardiometabolic Diseases Enabled by an AI-Platform Scalable for Future High-Value Indications Corporate Presentation January 2025
Slide 2: Forward-looking statements
Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "
Slide 3: An Antibody Discovery Platform for Cardiometabolic Disease and Beyond
3 An Antibody (Ab) Discovery Platform for Cardiometabolic Disease and Beyond Advancing Antibodies Against Difficult Targets With an Integrated and Validated AI Technology Stack Apply 2026 Obesity programs advance into clinic Scale 2029 Obesity programs advance to late clinical development Assets in
Slide 4: iBio's AI-Driven Antibody Discovery Platform Has Delivered
iBio's AI-Driven Antibody Discovery Platform Has Delivered Corporate Highlights • AI-driven antibody discovery Platform including patented Epitope steering, StableHu , EngageTx , and ShieldTx® • Platform has delivered Development Candidates in as little as 7 months • 11 active programs: 5 Cardiometa
Slide 5: Any Epitope on Any Drug Target
Any Epitope on Any Drug Target AI Epitope Engineering and Antibody Optimization Engines unlock challenging target classes • Multi-layer technology platform addresses multiple challenges in Ab discovery • Patented Epitope Steering technology • Single-step Ab StableHu x Mammalian Display • Masked (Shi
Slide 6: iBio's AI Tech Stack is a Fully Integrated Solution
6 iBio’s AI Tech Stack is a Fully Integrated Solution for Antibody Discovery Enables and accelerates Antibody Discovery & Development Against Hard-to-Drug Targets
Slide 7: Harnessing the Power of Our Platform in Cardio-metabolic Disease
Transition slide – Harnessing the Power of Our Platform to Address Challenges in Cardio-metabolic Disease
Slide 8: iBio's Rapidly Advancing Obesity and Cardiometabolic Pipeline
8 iBio’s Rapidly Advancing High Value Obesity and Cardiometabolic Pipeline Therapeutic Area Program Early Discovery Late Discovery Lead Optimization IND-Enabling Cardio-metabolic IBIO-600 Myostatin (obesity) Myostatin x Activin A (obesity/ potentially PH-HFpEF) Activin E (obesity) Target 3 (obesity)
Slide 9: Current Treatments in Obesity Fall Short
9 Current Treatments in Obesity Fall Short Significant Unmet Medical Need for Innovation to Improve Overall Metabolic Health and Function The Next Generation Potential Avenues: • Preservation of muscle mass during GLP-1 agonist induced weight loss • Improved fat burning and prevention of dyslipidemi
Slide 10: A Clear Strategy to Create a High-Value Pipeline
10 A Clear Strategy to Create a High-Value Pipeline of Differentiated Products A prime opportunity exists for GLP-1 complementary therapeutic approaches • Muscle mass loss • Side effects leading to discontinuation • Inconvenient dosing frequency • Room for high quality weight loss Address Challenges
Slide 11: IBIO-600 Long-Acting Anti-Myostatin Antibody
Transition slide – IBIO-600 Long-Acting Anti-Myostatin Antibody
Slide 12: Myostatin Antagonism
1. Schuelke M. (2004). New England Journal of Medicine 350(2682–2688). 2. Deng, B. (2017). Nutrition and Metabolism, 14(29). 12 Myostatin Antagonism Enhancing the Quality of Weight Loss by Maintaining Muscle Mass During and After Weight Loss with GLP-1s We are developing Myostatin inhibitors to pres
Slide 13: IBIO-600: A Long-Acting First-in-Class Anti-Myostatin Antibody
1. Data available on request IBIO-600: A Long-Acting First-in-Class Anti-Myostatin Antibody First Anti-Myostatin Antibody With a Target Product Profile Specifically Tailored for an Obese Patient Population IBIO-600 Long-Acting Anti-Myostatin Antibody First-in-class innovation: First Myostatin therap
Slide 14: IBIO-600 Increases Muscle Differentiation in Primary Human Myoblast Cells
14 IBIO-600 Increases Muscle Differentiation in Primary Human Myoblast Cells Red indicates muscle cell growth and development (as measured by myoblast differentiation) Myostatin Only Myostatin + IBIO-600 IBIO-600 potently increases myoblast differentiation Baseline human myoblast differentiation (un
Slide 15: Interim Data: IBIO-600 Preserves Muscle Mass in GLP-1 Treated Mice
Body weight loss up to day 14 In this study the murine surrogate antibody of IBIO-600 was used 15 Interim Data: IBIO-600 Preserves Muscle Mass in GLP-1 Treated Diet Induced Obesity Mice Day 14 Interim Data Collection Day -7 Day 1 Day 28 Day 56 Body composition Insulin tolerance test Grip Strength St
Slide 16: Anti-Myostatin x Activin A Bispecific Antibody
Transition slide – Anti-Myostatin x Activin A Bispecific Antibody
Slide 17: Combined Myostatin and Activin A Antagonism
17 Combined Myostatin and Activin A Antagonism Synergistic Effect on Muscle Growth and Potential Treatment for Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF) For obesity, we are developing bi-specific co-inhibitors of Myostatin and Activin A to enhance muscle g
Slide 18: Long-Acting First-in-Class Anti-Myostatin x Activin A Bispecific
• Well-tolerated for long-term use • Infrequent subcutaneous self-administration *Bone Morphogenetic Proteins A Long-Acting First-in-Class Anti-Myostatin x Activin A Bispecific Antibody Myostatin x Activin A Bi-specific Target product profile for obese and potentially Ph-HFpEF patients First-in-clas
Slide 19: Myostatin and Activin A Bi-Specific Synergistically Increases Muscle Mass
19 iBio’s Myostatin and Activin A Bi-Specific Targets Both Key Negative Muscle Regulators, Synergistically Increasing Muscle Mass Increased muscle fusion index in human muscle stem cells is a surrogate of muscle growth Negative control (Myostatin + Activin A) without antibody Myostatin + Activin A w
Slide 20: Anti-Activin E Antibody
inE Anti-Activi Antibody
Slide 21: Activin E Antagonism
Type 2 Diabetes (T2D) 21 Activin E Antagonism Attractive Fat-Specific Weight Loss Mechanism with Excellent Compatibility for Bi-Specific Pairing with Anti-Myostatin We are developing inhibitors of Activin E to promote fat-specific weight loss, either as a standalone drug or as a bi-specific antibody
Slide 22: First-in-Class Functional Antibody for Activin E
• First-in-class functional antibody for Activin E iBio’s AI-Enabled Epitope Steering Engine Bypasses Recombinant Activin E, Creating Functional Antibodies Directly from the Target Sequence Activin E Antibody AI epitope engineering breaks barrier to discovery Innovative AI solution: Epitope steering
Slide 23: AI Engineered Epitope Engine Delivers a Functional Activin E Antibody
23 iBio’s AI Engineered Epitope Engine Delivers a First-in-Class Functional Activin E Antibody Challenge We have uniquely solved an industry-wide problem with our proprietary epitope engineering engine to create functional Activin E antibodies iBio’s Solution Breakthrough Activin E Signaling (lower
Slide 24: Immuno-Oncology
Immuno-Oncology
Slide 25: Beyond Cardiometabolic – Our Oncology Pipeline
*Tumor Micro Environment 25 Beyond Cardiometabolic – Driving Value Within Our Oncology Pipeline Program MoA Potential Indications Early Discovery Late Discovery Lead Optimization IND-Enabling Highlights IBIO-101 Treg depletion, IL-2 sparing Solid tumors, orphan indications Synergistic efficacy with
Slide 26: A Leadership Team with Deep Industry Experience
26 A Leadership Team with Deep Industry Experience Deep expertise in cardiometabolic disorders Marc Banjak CLO Martin Brenner, DVM, Ph.D. CEO & CSO Kristi Sarno Senior VP BD Felipe Duran CFO
Slide 27: Executive Summary
Executive Summary Corporate Highlights • Patented AI-driven Discovery Tech Stack which can: • Rapidly advance a highly developable pre-clinical pipeline • Solve hard-to-drug problems • Pipeline of cardio/obesity rapidly progressing • Pipeline of immuno-oncology molecules ready for strategic partners
Slide 28: Appendix
Appendix
Slide 29: Technology Platform & Preclinical Pipeline
29 Technology Platform & Preclinical Pipeline
Slide 30: Technology Stack
30 Technology Stack
Slide 31: iBio's Tech Stack Aims to Solve Major Challenges in Antibody Discovery
31 iBio’s Tech Stack Aims to Solve Major Challenges in Antibody Discovery & Development Epitope Steering StableHu & Mammalian Display Unlocking Novel Biology Reduced Lead-Optimization Time Optimization in less than 4 weeks Minimized Developability Risk Mammalian Display in Manufacturing Cell Line Po
Slide 32: Tech Stack Addresses Immuno-oncology Discovery Challenges
32 iBio’s Tech Stack Addresses Immuno-oncology Discovery and Development Challenges ShieldTx 2nd Gen T-cell Engager Panel Finely tuned T-cell engagement Adjustable T-cell engagement to fit any tumor target engager Improved safety prediction Cyno cross reactivity allows for better preclinical safety
Slide 33: AI-Engineered Epitopes are Generalizable to Complex Drug Binding Sites
Match Engineered Structure to Target Refined for Greater Stability Optimized for Water Solubility 33 Unlocking High-Value Drug Targets: AI-Engineered Epitopes are Generalizable to a Broad Set of Complex Structural Drug Binding Sites Junctional Epitopes Complex Secondary Structures Membrane Proteins
Slide 34: StableHu Antibody Optimization & Mammalian Display Screening
Input Antibody StableHu AI-Engine Mammalian Display Output Antibody Template CDR Predict library of human CDR variants Single-cell screen mammalian display CDR library Optimized antibody with fully human CDRs 34 Accelerate Success: StableHu Antibody Optimization & Mammalian Display Screening Propel
Slide 35: ShieldTx Conditionally Activated Antibodies
35 “Smart” Antibodies: ShieldTx Conditionally Activated Antibodies Strive to Improve Safety by Selectively Targeting Diseased but not Healthy Tissue H+ Diseased Tissue “On-epitope, off-tissue” therapy Healthy Tissue “On-epitope, on-tissue” therapy DME activation Diseased Tissue “On epitope, on tissu
Slide 36: EngageTx, a CD3-Based T-Cell Engager Panel
36 EngageTx, a CD3-Based T-Cell Engager Panel, Addresses 3 Key Challenges: Cytokine Release, NHP Cross-Reactivity and Immunogenicity Risk Numerous tumor antigen arms Diverse CD3 engager arms 1 Sequence Diversity 2 Hu-Cyno Cross-Reactivity 3 Range of Cytokine Release Increased humanness and broad CD3
Slide 37: iBio's Platform Tackles Discovery Challenges for the Next Era of Antibodies
Epitope Engineering Engine* Proprietary Antibody Library AI-powered mammalian-display co-optimization of mono/multi-specific antibody and conditionally activated mask Engineered Epitope Steering AI-powered engineering of conformational epitopes Epitope-specific antigens that steer discovery to inten
Slide 38: IBIO-101 IL-2 Sparing Anti-CD25
38 IBIO-101 IL-2 Sparing Anti-CD25
Slide 39: IBIO-101 for Regulatory T-Cell Depletion
Recent Transactions & Milestones *Roche acquisition of Tusk Therapeutics completed for €70M upfront, acquiring worldwide rights to anti-CD25 program. Values converted to dollars as reported in public press releases **Data presented by Roche at AACR 2023 39 IBIO-101 for Regulatory T-Cell (Treg) Deple
Slide 40: IBIO-101 Selectively Depleting Immunosuppressive Tregs
Data on file. Treg = Regulatory T Cells; Teff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity 40 IBIO-101 Reduces Tumor Growth in Preclinical Studies by Selectively Depleting Immunosuppressive Tregs without Affecting Cancer Killing Teffs Indiscriminate depletion of Treg + Teff TU
Slide 41: IBIO-101 Selectively Depletes Tregs while Preserving IL-2 Signaling
RG6292 is Roche’s monoclonal antibody that targets CD25 (IL-2Rα). IBIO-101 data on file. 41 IBIO-101 Selectively Depletes Tregs while preserving IL-2 signaling IBIO-101 potently binds recombinant CD25 which leads to Treg depletion while sparing Teffs
Slide 42: IBIO-101 Increases Teff/Treg Ratio in Preclinical Studies
1hCD25 animal model - Data on file. 42 IBIO-101 Increases in Teff/Treg Ratio in Preclinical Studies Inhibiting Tumor Growth Tumor growth inhibition correlates with T-eff/T-reg ratio Potently increases T-eff/T-reg ratio1 * Significant vs * Significant vs Negative Control hIgG1 Isotype
Slide 43: IBIO-101 in Combination With a Checkpoint Inhibitor
*hCD25 animal model - Data on file. 43 IBIO-101 in Combination With a Checkpoint Inhibitor Shows Greater Efficacy IBIO-101 + PD-1 Checkpoint Inhibitor In PreClinical Studies Enhances Tumor Suppression * Significant vs Negative Control # Significant vs Anti-PD-1
Slide 44: IBIO-101 Favorable Characteristics for CMC Development
44 IBIO-101 is an Antibody With Favorable Characteristics for CMC Development • Identified manufacturing partner to produce IBIO-101 for Phase 1&2 clinical trials • Discovered suitable cell lines for manufacturing MCB • Established IBIO-101 CMC methodology for producing high yield, high purity, stab
Slide 45: Anti-CCR8 High ADCC
45 Anti-CCR8 High ADCC Anti -CCR8 for the Depletion of T-regulatory Cells
Slide 46: CCR8 for Tumor-Infiltrating Treg Depletion
*Fibrogen / HiFiBio: Fibrogen purchased option to multiple programs in June 2021, then exercised the option for excl. license to CCR8 program in Dec. 2021. **Gilead / Jounce: Exclusive worldwide license to anti-CCR8 antibody. *** Coherus / Surface Oncology: acquisition, announced in June 2023, adds
Slide 47: CCR8+ Treg Cells Are Tumor Infiltrating and Highly Immunosuppressive
Zheng, et al. Cell 169.7 (2017): 1342-1356; Whiteside, et al. Immunology 163(4) (2021): 512-520; Kidani, et al. PNAS 119(7) (2022): e2114282119 47 CCR8+ Treg Cells Are Tumor Infiltrating and Highly Immunosuppressive Depletion of CCR8+ Treg cells has potential to evoke potent tumor immunity • Systemi
Slide 48: Afucosylated Anti-CCR8 Antibody Specificity and Cell Killing
Data on file 48 Afucosylated Anti-CCR8 Antibody Exhibits High Specificity, CCL1 Antagonism and CCR8-Specific Cell Killing High Specificity CCR8 Cell Binding 0.0001 0.001 0.01 0.1 1 10 0 2 4 6 8 10 hCCR8 overexpressed cells Ab. (nM) MFI hIgG1 isotype mIgG2A isotype Anti -hCCR4 - EC50 = NA Anti-mCCR8
Slide 49: CCR8-Specific High ADCC Antibody Induces Tumor Regression
49 iBio’s CCR8-Specific High ADCC Antibody Induces Tumor Regression in a Transgenic Human CCR8 Mouse Model Day -7 Day 0 Day 0, 3, 7, 10 Tumor implantation Subsequent dosing Test article dosing (i.p) 0 2 4 6 8 10 12 14 0 50 100 150 200 250 300 Days after treatment Tumor Volume (mm3 ) * * * * p<0.05 v
Slide 50: EngageTx Versatile CD3 mAb Panel
50 Unlocking the Power of Bi-Specific Antibodies with EngageTx, Our Versatile CD3 mAb Panel Wide Range of Affinities, NHP Cross Reactivity, High Developability
Slide 51: Next Generation Anti-CD3 T Cell Engagers
*Eli Lilly / Merus: Fibrogen Research collaboration using Merus’ proprietary platform to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. ** GSK WuXi: License of WuXi’s preclinical CD3 bi-specific, plus 3 earlier stage programs ***Amgen / Teneobio: Teneobio was dev
Slide 52: Dual Approaches to a Diverse Panel of Anti-CD3 Antibodies
Data on file 52 Dual Approaches to a Diverse Panel of Anti-CD3 Antibodies Hu/Cyno CD3 & T Cell TCR CD3 Engineered Epitopes T Cell Template 1 Template 2 Structural-Epitope Immunization & Screening StableHu Optimizer AI Discovery Engine AI-Engineered Immunogens Epitope & T Cell Immunization Epitope &
Slide 53: Libraries and Screens Discover Hu-Cyno CD3 Cross-Reactive Antibodies
Data on file 53 Libraries and Screens Discover Hu-Cyno CD3 Cross-Reactive Antibodies Epitope-Steered Immunization Human T Cell Binding Selected Hit Low Medium High StableHu Mammalian-Display Not Selected Library Screen:
Slide 54: EngageTx Selected for Diversity of T Cell Binding and Activation
Data on file 54 EngageTx is Selected for a Diversity of T Cell Binding and Activation EC50: 3 – 570 nM EC50: 2.5 – 70 nM Human T Cell Binding EC50 (nM) CD69 T Cell Activation EC50 (nM) Hit Clones Hit Clones T Cell Assay: Ab Concentration (nM) IFN-γ (pg/mL) TNF-⍺ (pg/mL) IL-2 (pg/mL) ID 1 2 3 5 (-) C
Slide 55: ShieldTx Antibody Masking Technology
55 ShieldTx Antibody masking technology for delivering on-epitope, on-tissue clinical candidates with enhanced safety and developability
Slide 56: On-Target-Off-Tissue Side Effects Limit Existing Antibodies
Diseased Tissue Healthy Tissue 56 On-Target-Off-Tissue Side Effects Severely Limit The Potential of Existing And Future Antibodies Even exquisitely specific antibodies fail in clinical trials by doing exactly what they are asked to do – hit the target. The problem often lies in the target being also
Slide 57: Engineered Epitopes Provide an Integrated Masking Solution
57 Our Engineered Epitopes Provide an Integrated Solution for Identifying And Subsequently Masking Antibodies Diseased Tissue “On-epitope, off-tissue” therapy Healthy Tissue DME activation “On-epitope, on-tissue” therapy H+ DME: Disease Micro Environment Antibodies are activated by the removal of th
Slide 58: Masked Antibodies are a Proven Concept
58 Masked Antibodies are a Proven Concept and iBio’s Platform has the Potential to Solve Key Remaining Challenges THE PROBLEM OUR SOLUTION 1 Separate antibody and mask discovery process is inefficient Co-discovery of epitope-steered antibody and mask is more efficient Discovery process 2 Separate di
Slide 59: Anti-Trop-2 x CD3 Bi-Specific Antibody
59 Anti-Trop-2 x CD3 Bi-Specific Antibody against Tumor-Specific Trop-2 Cancer Cells
Slide 60: Trop-2 x CD3 Bi-Specific Antibody
Gilead acquired Immunomedics (Sept 2020): $21Bn Payment Trodelvy: Approval 60 Trop-2 x CD3 Bi-Specific Antibody Potentially for Head & Neck and Other Cancer Select killing cancer cells that up-regulate Trop-2 expression while improving safety margin in reducing cytokine release syndrome (CRS) • Head
Slide 61: Trop-2 x CD3 Bi-Specific Antibody Selective Target
Tumor cells show significantly increased Trop-2 expression Tumor cell death with high Trop-2 expression Trop-2 x CD3 binds to tumor cells Trop-2 x CD3 recruits T cells to kill tumor cells 61 Trop-2 x CD3 Bi-Specific Antibody Selective Target Overexpress Trop-2 Cancer Cells Trop-2 Tumor cell Healthy
Slide 62: Trop-2 x CD3 Potently Kills Tumor Cells with Low Cytokine Release
62 iBio’s Trop-2 x CD3 Bi-Specific Antibody Potently Kills Tumor Cells with Low Cytokine Release 62 0.0001 0.001 0.01 0.1 1 10 0 20 40 60 80 100 Ab (nM) % of Cell Killing ID EC50 (pM) Cmax (% killing) SD-753019 1.4 92% SD-231831 7.2 92% SD-753019 (Trop-2 x CD3SP34 Gen1) SD-231831 (Trop-2 x CD3iBio)
Slide 63: Single Dose Induces Tumor Regression in Humanized Mouse Model
63 A Single Dose of iBio’s Bispecific Trop-2 x CD3 Antibody Induces Tumor Regression in a Humanized Mouse Cancer Model 0 7 14 0 50 100 150 200 250 Days after tumor implantation Tumor volume (mm 3 ) Vehicle SD-231831 (1 mg/kg) Trop-2 x CD3iBio * * * * p<0.05 vs vehicle Single dose SD-231831 36% tumor
Slide 64: Conditionally Activated Anti-MUC16 x CD3 Bispecific Antibodies
64 Conditionally Activated Anti -MUC16 x CD3 Bispecific Antibodies Targeting the Non -Shed MUC16 Region Leveraging iBio’s Epitope Steering, ShieldTx, and EngageTx Technologies
Slide 65: MUC16 Potentially for Ovarian and Other Cancers
+Regeneron MUC16xCD3 (Sept 2022): Ph. 1 31% ORR Ph. 2 enrollment *Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND ** Liu et al., An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovar
Slide 66: MUC16 Is Overexpressed and Shed by Tumor Cells
66 MUC16 Is Overexpressed and Shed by Tumor Cells O-glycosylation N-glycosylation MUC16 epitope shedding Shedding eliminates the epitope and creates an antigen sink for most MUC16 antibodies Antibodies that bind the non-shed domain maintain activity N-terminal and tandem repeat (TR) domains that are
Slide 67: Immunizations Steered to a Non-Shed MUC16 Epitope
Weeks 1–2 Weeks 3–4 Week 5 67 Immunizations Were Steered to a MUC16 Epitope that Avoids Epitope Shedding Engineered Epitope Prime + MUC16 Cell Boost AI Discovery Engine MUC16 Engineered Epitope Structural-epitope Immunization & Screening Engineered Epitope ELISA Screen MUC16 OVCAR-3 MUC16high Cell B
Slide 68: Top Three Hit Clones Bind Non-Glycosylated MUC16 Epitope
68 Top Three Hit Clones Bind the Non-Glycosylated MUC16 Epitope Closest to the Membrane 1D7 8G4 21G6 Hits do not bind shed 230-mer Hits bind non-glycosylated non-shed 29-mer binding time O-glycosylation N-glycosylation N-terminal and tandem repeat (TR) domains that are shed Epitope KD = 8.0 nM KD =
Slide 69: Top MUC16 Clone 8G4 Binds OVCAR-3 Cells
69 Top MUC16 Clone 8G4 Binds OVCAR-3 Cells Comparable to Regeneron Benchmark Regeneron benchmark Clone ID: Secondary Only Unstained OVCAR-3 Cells 8G4 top clone higher cell binding Mode Normalized Data on file
Slide 70: 8G4 Clone Maintains Binding in a Fully Human Framework
70 8G4 Clone Maintains OVCAR-3 Cell and MUC16 Epitope Binding in a Fully Human Framework 8G4 with fully human framework reduces immunogenicity risk Glycosylated MUC16 membrane-proximal epitope SPR: KD = 5.1 nM Iso. Ctl OVCAR-3 Cells Epitope binding Cell binding higher cell binding Data on file
Slide 71: Efficient Expression with 2x2 Format
71 Efficient Expression with 2x2 Format: Anti-CD3 x MUC16 Bispecific T-Cell Engagers scFv-Fc 2x2 Anti-MUC16 TAA Anti-CD3 (EngageTx) CD3 MUC16 TAA T Cell Tumor Cell T Cell mediated killing
Slide 72: 2x2 Anti-CD3 x MUC16 T Cell Engagers Stimulate T Cells
EC50 = 14 nM EC50 = 62 nM EC50 = 19 nM EC50 = 126 nM Data on file 72 2X2 Anti-CD3 X MUC16 T Cell Engagers Stimulate T Cells in Donor PBMCs EC50 >> 100 nM EC50 >> 100 nM MUC16 Arm 1 (-)CD3 Arm only Epitope-Steered Immunized Hit StableHu Hit CD69 MFI Concentration (nM) MUC16 Arm 2 CD3 Arms MUC16 Arms
Slide 73: 2x2 Anti-CD3 x MUC16 T Cell Engagers Kill OVCAR-3 Cells
EC50 = 4.0 nM EC50 = 2.5 nM EC50 = 5.2 nM EC50 = 5.2 nM Data on file 73 2X2 Anti-CD3 X MUC16 T Cell Engagers Kill OVCAR-3 Ovarian Cancer Cells EC50 >> 100 nM EC50 >> 100 nM MUC16 Arm 1 (-)CD3 Arm only Epitope-Steered Immunized Hit StableHu Hit Concentration (nM) MUC16 Arm 2 CD3 Arms MUC16 Arms % Spe
Slide 74: ShieldTx Mask Conditionally Activates MUC16 and CD3 Hits
Data on file 74 ShieldTx Engineered Epitope Mask Conditionally Activates MUC16 and CD3 Hits Mask Cleavage No Mask Mask (–MMP9) Mask (+MMP9) MMP protease Engineered Epitope Mask Intact Inactive Antibody Active Antibody Anti-MUC16 hit Anti-CD3 hit MUC16 Binding Response CD3 Binding Response time (s)
Slide 75: Anti-EGFRvIII High ADCC mAb
75 Anti-EGFRvIII High ADCC mAb Against Tumor-Specific EGFRvIII Cells
Slide 76: EGFRvIII Potentially for Glioblastoma and Other Cancers
**Seagen / LAVA Therapeutics (Sep 2022): $50M upfront, $650M milestones ***Taiho / Cullinan Oncology (May 2022): $275M upfront, $130M milestones * Pierre Fabre / Scorpion: Scorpion licensed two preclinical-stage programs to Pierre Fabre which are targeted to specific EGFR mutations in lung cancer. *
Slide 77: Anti-EGFRvIII mAbs Selectively Kill EGFRvIII-Positive Tumor Cells
Skin toxicity No skin damage Data on file 77 iBio’s Anti-EGFRvIII mAbs Selectively Kill EGFRvIII-Positive Tumor Cells and Not EGFR1-Expressing Cells in Healthy Tissues iBio mAb binding specifically to EGFRvIII Tumor Size Reduction iBio mAb doesn’t bind to EGFR1 in skin Non-EGFRvIII specific mAb bind
Slide 78: EGFRvIII-Selective mAbs Kill Tumor Cells without Affecting Healthy Cells
Data on file 78 iBio’s EGFRvIII-Selective mAbs Kill Tumor Cells without Affecting Healthy Cells iBio EGFRvIII mAbs bind recombinant EGFRvIII which leads to tumor cell killing but not binding wild-type EGFR1 and thus not affecting healthy cells
Slide 79: EGFRvIII-Specific Antibody Inhibits Tumor Growth in Xenograft Model
79 iBio’s EGFRvIII-Specific High-ADCC Antibody Inhibits Tumor Growth in an EGFRvIII Tumor Xenograft Mouse Model Day -7 Day 0 Day 0, 3, 8, 11, 14, 17 Tumor implantation Subsequent dosing Test article dosing (i.v.) 0 5 10 15 20 25 0 200 400 600 800 1000 1200 1400 1600 1800 Days after treatment Tumor V
Slide 80: Market-Tested Potential in Immuno-Oncology
80 Market-Tested Potential in Immuno-Oncology Competitor Early-Stage Deals Signal Promising Opportunities
Slide 81: Market-Tested Potential: Immuno-Oncology Early-Stage Deals
* Acquisition / Merger + License or collaboration 81 Market-Tested Potential: Immuno-Oncology Early-Stage Deals CCR8 Coherus / Surface Oncology*: acquired for $65M JUN 2023 Pre-2020 2021 2022 2023 CCR8 Gilead / Jounce+: $85M upfront, $35M equity investment, $685M milestones SEP 2020 FEB 2021 PD-1 ag